Page 87 - DUOKOPT BIBLIOBOOK

EFFICACY

IOP-Lowering Effects of Fixed-Combination Drugs

Quality score 14 15 13 16 15 18 16 18 16 16 16 14 17 18 16 16 14

IOP* ] (SD)
Baseline Hg) (mm [mean (2.1) 23.1 (2.9) 27.2 (2.2) 24.0 (1.6) 22.9 (2.6) 27.1 (3.1) 25.9 (2.0) 25.1 (3.4) 26.2 (1.6) 26.4 (2.7) 27.2 (2.8) 26.9 (4.0) 24.0 (3.3) 28.9 (6.9) 27.3 (1.9) 27.7 (4.6) 23.3 (1.3) 24.7

or (%)
POAG OHT 100 100 100 100 100 100 100 99 100 95 100 100 100 91 100 100 100

Sex (M/F) 8/19 13/21 15/14 12/18 21/32 247/286 11/18 47/70 11/16 80/91 18/10 87/123 15/19 181/256 13/16 80/100 8/10
age
Mean (years) 57.5 62.4 64.9 56.1 61.2 62.1 68.0 61.8 61.0 - 63.6 60.4 63.9 64.8 63.7 67.7 57.8

Withdrawals (%) 0.0 2.9 3.3 0.0 8.6 6.6 3.3 6.0 0.0 7.5 12.5 7.6 5.9 10.1 3.3 10.6 0.0

Total no. 27 34 29 30 53 533 29 117 27 171 28 210 34 437 29 180 18

Duration Weeks Weeks Months Weeks Months Months Weeks Weeks Weeks Months Months Weeks Weeks Months 12 Weeks Months Weeks

PM 6 8 6 PM 4 PM 6 PM 3 8 PM 8 PM 6 PM 6 PM 3 PM 8 PM 8 PM 8 3 PM 8
9 8 8 8 8 8 8 8 8 8 8 8
Route AM, 9 PM 8 AM, 8 AM, 8 AM, 8 AM 8 AM, 8 AM, 8 AM, 8 AM, 8 AM, 8 AM, 8 PM 10 AM, 8 PM 8 AM, 8 PM 8

Intervention Medication Dorzolamide/ 2.0% timolol 0.5% Latanoprost/ 0.005% timolol 0.5% Dorzolamide/ 2.0% timolol 0.5% Brimonidine/ 0.2% 2.0% timolol 0.5% Dorzolamide/ timolol 0.5% Dorzolamide/ 2.0% timolol 0.5% Bimatoprost/ 0.03% timolol 0.5% Dorzolamide/ 2.0% timolol 0.5% Dorzolamide/ 2.0% timolol 0.5% Dorzolamide/ 2.0% timolol 0.5% Brinzolamide/ 1.0% timolol 0.5% Brimonidine/ 0.2% timolol 0.5% Bri

Centre 1 1 1 1 2 59 2 19 1 35 2 5 1 Multi 1 10 1

Location Brazil Greece Turkey Brazil Greece Canada U.S., U.S. U.S. Greece U.S. Greece Brazil, Argentina Greece Europe, U.S., Australia, Singapore, Taiwan Greece U.S. Brazil

Design PG SB, CR SB, CR SB, CR SB, CR SB, PG DB, CR DB, PG DB, CR SB, PG DB, CR SB, PG OL, CR DB, PG DB, CR DB, PG SB, PG OL,

Cont.

2. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44]
Table Trial 200609/02 200611/01 200702/01 200704/01 200801/01 200804/01 200808/01 200808/02 200810/01 200810/02 200811/01 200812/01 200904/01 200904/02 200905/01 200907/01 200910/01

PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45079 87